Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
283 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2016', provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy - The report reviews pipeline therapeutics for Duchenne Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Duchenne Muscular Dystrophy therapeutics and enlists all their major and minor projects - The report assesses Duchenne Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Duchenne Muscular Dystrophy Overview 10 Therapeutics Development 11 Pipeline Products for Duchenne Muscular Dystrophy - Overview 11 Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 12 Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 13 Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 18 Duchenne Muscular Dystrophy - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Duchenne Muscular Dystrophy - Products under Development by Companies 23 Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 28 Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 29 Acceleron Pharma, Inc. 29 Anagenesis Biotechnology 30 Asklepios BioPharmaceutical, Inc. 31 BioMarin Pharmaceutical Inc. 32 Bristol-Myers Squibb Company 33 Capricor Therapeutics, Inc. 34 Catabasis Pharmaceuticals, Inc. 35 Daiichi Sankyo Company, Limited 36 Debiopharm International SA 37 Editas Medicine, Inc. 38 EryDel SPA 39 FibroGen, Inc. 40 Galapagos NV 41 Genethon 42 GTx, Inc. 43 GW Pharmaceuticals Plc 44 Idera Pharmaceuticals, Inc. 45 Italfarmaco S.p.A. 46 La Jolla Pharmaceutical Company 47 Lexicon Pharmaceuticals, Inc. 48 Marathon Pharmaceuticals, LLC 49 Marina Biotech, Inc. 50 Merck KGaA 51 Milo Biotechnology LLC 52 Mitochon Pharmaceuticals, Inc. 53 MyoTherix Inc. 54 NicOx S.A. 55 Nippon Shinyaku Co., Ltd. 56 Nobelpharma Co., Ltd. 57 Pfizer Inc. 58 Pluristem Therapeutics Inc. 59 Prothelia, Inc. 60 PTC Therapeutics, Inc. 61 RASRx, LLC 62 ReveraGen BioPharma, Inc. 63 Santhera Pharmaceuticals Holding AG 64 Sarepta Therapeutics, Inc. 65 Summit Therapeutics Plc 66 Taiho Pharmaceutical Co., Ltd. 67 WAVE Life Sciences Ltd. 68 Zambon Company S.p.A. 69 Duchenne Muscular Dystrophy - Therapeutics Assessment 70 Assessment by Monotherapy Products 70 Assessment by Target 71 Assessment by Mechanism of Action 74 Assessment by Route of Administration 77 Assessment by Molecule Type 79 Drug Profiles 81 4-P001 - Drug Profile 81 AAV1-Foliistatin - Drug Profile 82 ACE-083 - Drug Profile 84 alisporivir - Drug Profile 86 Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 89 Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 90 Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 91 Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy - Drug Profile 92 Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile 93 Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 94 arbekacin - Drug Profile 95 ARM-210 - Drug Profile 96 AT-300 - Drug Profile 98 ataluren - Drug Profile 100 Biostrophin - Drug Profile 108 BMBD-001 - Drug Profile 109 BMS-986089 - Drug Profile 110 CAP-1002 - Drug Profile 111 CAP-2003 - Drug Profile 116 CAT-1004 - Drug Profile 117 DA-4210 - Drug Profile 121 deflazacort - Drug Profile 122 dexamethasone sodium phosphate - Drug Profile 124 domagrozumab - Drug Profile 126 Drug for Duchenne Muscular Dystrophy - Drug Profile 128 Drugs for Duchenne Muscular Dystrophy - Drug Profile 129 DS-5141 - Drug Profile 130 DT-200 - Drug Profile 131 enobosarm - Drug Profile 132 eteplirsen - Drug Profile 139 ezutromid - Drug Profile 150 Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile 156 Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile 157 Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 158 Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 159 Gene Therapy to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 160 givinostat - Drug Profile 161 Gtx-027 - Drug Profile 163 IB-DMD - Drug Profile 164 idebenone - Drug Profile 165 IMO-8400 - Drug Profile 173 LJPC-30Sa - Drug Profile 179 LJPC-30Sb - Drug Profile 180 LX-2931 - Drug Profile 181 MG-53 - Drug Profile 183 MP-101 - Drug Profile 185 Myomir - Drug Profile 186 naproxcinod - Drug Profile 187 NS-065 - Drug Profile 190 Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 191 Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 192 Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 193 Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 194 OSX-200 - Drug Profile 195 pamrevlumab - Drug Profile 196 PLX-PAD - Drug Profile 202 poloxamer - Drug Profile 211 PRO-052 - Drug Profile 213 PRO-055 - Drug Profile 215 PRT-01 - Drug Profile 217 Recombinant Protein for Muscular Dystrophy - Drug Profile 219 Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile 220 Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile 221 rimeporide - Drug Profile 222 RTC-13 - Drug Profile 223 SB-001 - Drug Profile 225 SB-002 - Drug Profile 226 SGT-001 - Drug Profile 227 Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 228 Small Molecules for Duchenne Muscular Dystrophy - Drug Profile 229 Small Molecules for Duchenne Muscular Dystrophy - Drug Profile 230 Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 231 Small Molecules to Agonize Cannabinoid Receptor for Duchenne Muscular Dystrophy - Drug Profile 232 SMT-022357 - Drug Profile 233 SRP-4008 - Drug Profile 235 SRP-4044 - Drug Profile 236 SRP-4045 - Drug Profile 237 SRP-4050 - Drug Profile 238 SRP-4052 - Drug Profile 239 SRP-4053 - Drug Profile 240 SRP-4055 - Drug Profile 241 Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 242 Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 244 Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 245 Stryka-516 - Drug Profile 246 Stryka-969 - Drug Profile 247 StrykaPro-1 - Drug Profile 248 Synthetic Peptides for Duchene Muscle Dystrophy - Drug Profile 249 TAS-205 - Drug Profile 250 TVN-102 - Drug Profile 251 TXA-127 - Drug Profile 252 vamorolone - Drug Profile 256 ZP-049 - Drug Profile 258 Duchenne Muscular Dystrophy - Dormant Projects 259 Duchenne Muscular Dystrophy - Discontinued Products 263 Duchenne Muscular Dystrophy - Product Development Milestones 264 Featured News & Press Releases 264 Appendix 275 Methodology 275 Coverage 275 Secondary Research 275 Primary Research 275 Expert Panel Validation 275 Contact Us 275 Disclaimer 276
List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2016 18 Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2016 25 Comparative Analysis by Late Stage Development, H2 2016 26 Comparative Analysis by Clinical Stage Development, H2 2016 27 Comparative Analysis by Early Stage Development, H2 2016 28 Comparative Analysis by Unknown Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2016 36 Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnology, H2 2016 37 Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016 38 Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2016 39 Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H2 2016 40 Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics, Inc., H2 2016 41 Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 42 Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 43 Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA , H2 2016 44 Duchenne Muscular Dystrophy - Pipeline by Editas Medicine, Inc., H2 2016 45 Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H2 2016 46 Duchenne Muscular Dystrophy - Pipeline by FibroGen, Inc., H2 2016 47 Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2016 48 Duchenne Muscular Dystrophy - Pipeline by Genethon, H2 2016 49 Duchenne Muscular Dystrophy - Pipeline by GTx, Inc., H2 2016 50 Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H2 2016 51 Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 52 Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H2 2016 53 Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2016 54 Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 55 Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016 56 Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016 57 Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2016 58 Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2016 59 Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016 60 Duchenne Muscular Dystrophy - Pipeline by MyoTherix Inc., H2 2016 61 Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H2 2016 62 Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 63 Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H2 2016 64 Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2016 65 Duchenne Muscular Dystrophy - Pipeline by Pluristem Therapeutics Inc., H2 2016 66 Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2016 67 Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2016 68 Duchenne Muscular Dystrophy - Pipeline by RASRx, LLC, H2 2016 69 Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2016 70 Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 71 Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016 72 Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H2 2016 73 Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 74 Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016 75 Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2016 76 Assessment by Monotherapy Products, H2 2016 77 Number of Products by Stage and Target, H2 2016 79 Number of Products by Stage and Mechanism of Action, H2 2016 82 Number of Products by Stage and Route of Administration, H2 2016 85 Number of Products by Stage and Molecule Type, H2 2016 87 Duchenne Muscular Dystrophy - Dormant Projects, H2 2016 266 Duchenne Muscular Dystrophy - Dormant Projects (Contd..1), H2 2016 267 Duchenne Muscular Dystrophy - Dormant Projects (Contd..2), H2 2016 268 Duchenne Muscular Dystrophy - Dormant Projects (Contd..3), H2 2016 269 Duchenne Muscular Dystrophy - Discontinued Products, H2 2016 270
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
